Erasca (ERAS) Accumulated Expenses (2020 - 2026)
Erasca posted quarterly Accumulated Expenses of $19.2 million for Q1 2026, up 231.1% year-on-year from $5.8 million in Q1 2025, and down 14.31% on a QoQ basis from $22.5 million in Q4 2025.
Erasca (ERAS) has 7 years of Accumulated Expenses data on file, last reported at $19.2 million in Q1 2026.
- For the quarter ending Q1 2026, Accumulated Expenses rose 231.1% year-over-year to $19.2 million; the trailing twelve-month figure through Mar 2026 stood at $19.2 million (up 231.1% YoY), and the FY2025 full-year result was $22.5 million, down 14.61% from the prior year.
- Accumulated Expenses for Q1 2026 stood at $19.2 million, down from $22.5 million in the prior quarter.
- Across five years, Accumulated Expenses topped out at $26.3 million in Q4 2024 and bottomed at $178000.0 in Q1 2024.
- The 5-year median for Accumulated Expenses is $8.5 million (2023), against an average of $12.7 million.
- The widest annual swing landed in 2024, when Accumulated Expenses sank 99.07%; it then surged 3166.29% in 2025.
- A 5-year view of Accumulated Expenses shows it stood at $24.3 million in 2022, then tumbled by 57.63% to $10.3 million in 2023, then soared by 155.14% to $26.3 million in 2024, then declined by 14.61% to $22.5 million in 2025, then decreased by 14.31% to $19.2 million in 2026.
- The last three Accumulated Expenses figures came in at $19.2 million (Q1 2026), $22.5 million (Q4 2025), and $20.8 million (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn |
| 10 | Erasca | 4.21 Bn | 3.97 Bn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 19.25 Mn |
| Dec 31, 2025 | 22.46 Mn |
| Sep 30, 2025 | 20.80 Mn |
| Jun 30, 2025 | 6.64 Mn |
| Mar 31, 2025 | 5.81 Mn |
| Dec 31, 2024 | 26.31 Mn |
| Sep 30, 2024 | 8.00 Mn |
| Jun 30, 2024 | 6.15 Mn |
| Mar 31, 2024 | 178,000.00 |
| Dec 31, 2023 | 10.31 Mn |
| Sep 30, 2023 | 8.50 Mn |
| Jun 30, 2023 | 6.27 Mn |
| Mar 31, 2023 | 19.05 Mn |
| Dec 31, 2022 | 24.34 Mn |
| Sep 30, 2022 | 7.10 Mn |
| Jun 30, 2022 | 19.83 Mn |
| Mar 31, 2022 | 4.57 Mn |
| Dec 31, 2021 | 21.26 Mn |
| Sep 30, 2021 | 4.71 Mn |
| Jun 30, 2021 | 6.31 Mn |
| Dec 31, 2020 | 2.42 Mn |